Granisetron intranasal - Shin Nippon Biomedical Laboratories
Alternative Names: Granisetron intranasal - Translational Research; Nasal granisetron (TRG) - Shin Nippon Biomedical Laboratories (SNBL); TRGLatest Information Update: 02 Oct 2021
At a glance
- Originator Translational Research
- Developer Shin Nippon Biomedical Laboratories
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Chemotherapy-induced nausea and vomiting
Highest Development Phases
- Phase II Chemotherapy-induced nausea and vomiting
Most Recent Events
- 23 Jun 2015 Granisetron intranasal is still in active development for Chemotherapy-induced nausea and vomiting in USA
- 15 Oct 2013 Granisetron intranasal - Shin Nippon Biomedical Laboratories is available for licensing as of 15 Oct 2013. http://www.snbl-nds.co.jp
- 08 Oct 2013 Phase-II development has been completed in USA and Shin Nippon Biomedical Industries is preparing for pivotal phase III trials in the US